ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

Lignende værker

• ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response
  af: Swartjes, Maarten, et al.
  Udgivet: (2014)
• ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats
  af: Muller, Carole, et al.
  Udgivet: (2015)
• ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density
  af: Dahan, Albert, et al.
  Udgivet: (2013)
• Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density
  af: Albert Dahan, et al.
  Udgivet: (2016-09-01)
• Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
  af: Brines, Michael, et al.
  Udgivet: (2008)